Extracellular Vesicle Treatment Alleviates Neurodevelopmental and Neurodegenerative Pathology in Cortical Spheroid Model of Down Syndrome.
Extracellular Vesicle Treatment Alleviates Neurodevelopmental and Neurodegenerative Pathology in Cortical Spheroid Model of Down Syndrome.
复制标题
DOI:
10.3390/ijms24043477
复制
发表时间:
2023-02-09
影响因子:
5.6
通讯作者:
中科院分区:
文献类型:
--
作者:
Down syndrome (DS), or trisomy 21, is manifested in a variety of anatomical and cellular abnormalities resulting in intellectual deficits and early onset of Alzheimer’s disease (AD) with no effective treatments available to alleviate the pathologies associated with the disorder. The therapeutic potential of extracellular vesicles (EVs) has emerged recently in relation to various neurological conditions. We have previously demonstrated the therapeutic efficacy of mesenchymal stromal cell-derived EVs (MSC-EVs) in cellular and functional recovery in a rhesus monkey model of cortical injury. In the current study, we evaluated the therapeutic effect of MSC-EVs in a cortical spheroid (CS) model of DS generated from patient-derived induced pluripotent stem cells (iPSCs). Compared to euploid controls, trisomic CS display smaller size, deficient neurogenesis, and AD-related pathological features, such as enhanced cell death and depositions of amyloid beta (Aβ) and hyperphosphorylated tau (p-tau). EV-treated trisomic CS demonstrated preserved size, partial rescue in the production of neurons, significantly decreased levels of Aβ and p-tau, and a reduction in the extent of cell death as compared to the untreated trisomic CS. Together, these results show the efficacy of EVs in mitigating DS and AD-related cellular phenotypes and pathological depositions in human CS.
登录
查看更多内容
DOI:
10.1073/pnas.2200944119
发表时间:
2022-11
影响因子:
11.1
作者:
通讯作者:
--
DOI:
10.3390/v15010142
发表时间:
2023-01-01
期刊:
Viruses
影响因子:
--
作者:
Contreras D;Garcia G Jr;Jones MK;Martinez LE;Jayakarunakaran A;Gangalapudi V;Tang J;Wu Y;Zhao JJ;Chen Z;Ramaiah A;Tsui I;Kumar A;Nielsen-Saines K;Wang S;Arumugaswami V
通讯作者:
Arumugaswami V
影响因子:
11
作者:
Gonzalez C;Armijo E;Bravo-Alegria J;Becerra-Calixto A;Mays CE;Soto C
通讯作者:
Soto C
影响因子:
5.3
作者:
Chakrabarti, Lina;Galdzicki, Zygmunt;Haydar, Tarik F.
通讯作者:
Haydar, Tarik F.
DOI:
10.1111/cts.12491
发表时间:
2018-03
期刊:
Clinical and translational science
影响因子:
--
作者:
Cummings J
通讯作者:
Cummings J